Gregory L. Verdine is the Erving Professor of Chemistry and Harvard College Professor, emeritus, at Harvard University and Harvard Medical School, and co-founder, President and CEO of LifeMine Therapeutics and VidaVinci. A leading chemical biologist and entrepreneur, he helped found chemical biology and new-modality therapeutics, coined “Drugging the Undruggable,” and invented stapled peptides. His work enabled daraxonrasib, the first drug to double lifespan in pancreatic cancer, plus FOG-001, LIFE-001, and stereopure oligonucleotide therapeutics. He is a Fellow of the Royal Society of Chemistry and AAAS, and has received the Nobel Laureate Signature Award, the AACR Award for Excellence in Chemistry in Cancer Research, and recognition as a 2026 Honoree of the American Academy of Achievement. He earned his B.S. from St. Joseph’s University and Ph.D. from Columbia University, and holds an honorary Ph.D. from Clarkson University.